Amgen (AMGN) Tops Q2 EPS by 38c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Amgen Reports Second Quarter 2019 Financial Results
July 30, 2019 4:01 PM EDTTHOUSAND OAKS, Calif., July 30, 2019 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2019. Key results include:
Total revenues decreased 3% to $5.9 billion in comparison to the second quarter of 2018 reflecting increasing competition due to patent expirations. Product sales declined 2% globally. Prolia® (denosumab), Repatha® (evolocumab), Parsabiv® (etelcalcitide) and Aimovig® (erenumab-aooe) units grew double-digits or better.GAAP earnings per share (EPS) increased 3% to $3.57 benefited by lower weighted-average shares outstanding. GAAP operating income decreased 5% to $2.7 billion and GAAP operating margin decreased 1.9 percentage... More